PUBLIC COMPANY
save$CRNXCrinetics Pharmaceuticals, Inc.
$CRNX84.950.00%San Diego, CA, USupdated 1mo ago
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
community read0 votes
pipeline
4
marketed
1
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(4)
pipeline depth4 products
1Phase 21Phase 31Marketed1Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase2Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)
- phase3A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
- phase2A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
- phase3A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
- phase3A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
- phase3A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
- phase2A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)
- phase2Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
🐶 Hiring Signal
News
- M&A slows in Q3 but Vertex snags one of the year’s biggest in $10B Crinetics buyAfter a frantic second quarter, M&A steadied with just under $30 billion across 22 total transactions, according to a BioSpace analysis.biospace · 3d ago
- Vertex was sole bidder in high-premium Crinetics acquisitionAnalysts expect new details on the lead-up to the deal “are likely to reignite” investor scrutiny that Vertex overpaid in what’s poised to be its largest-ever transaction.biopharma_dive · 2mo ago
- Vertex was only bidder for Crinetics in year's second-highest M&A premiumTo gain control of Crinetics Pharmaceuticals, Vertex Pharmaceuticals was willing to pay the second-highest premium so far in biopharma's banner year for M&A. And the Boston drugmaker was bidding ag…endpoints · 2mo ago
- STAT+: Compass says depression drug has long-lasting benefitsVertex makes its largest-ever deal, skyrocketing health insurance costs, and more biotech news from The Readoutstat · 2mo ago
- Vertex to acquire Crinetics in $10B foray into endocrine disease drugsVertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.biopharma_dive · 2mo ago
- STAT+: Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A boomsVertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals and its drug for a rare endocrine disorder, the companies said.stat · 3mo ago
Data sources
last refreshed 34m ago
Found something off?
comments(0)
5-min edit window · permanent after that